AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33586920 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multimodal symptom-management program plus usual care
Number of subjects: 50
Study 33586920 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 35412592 — intervention group
Group type: COMPARATOR
Intervention: Standard educational materials alone
Number of subjects: 300
Study 35412592 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard educational materials in combination with web-based decision support tools
Number of subjects: 300
Study 34625027 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary haemoglobin measurement using a haemoglobinometer on a monthly basis
Number of subjects: 0
Study 34625027 — intervention group
Group type: COMPARATOR
Intervention: Current protocol at the primary care centre with venous haemoglobin measurement
Number of subjects: 0
Study 36178742 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 200
Study 36178742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 33554398 — intervention group
Group type: EXPERIMENTAL
Intervention: Child labor
Number of subjects: 947
Study 33554398 — intervention group
Group type: COMPARATOR
Intervention: Nonworking siblings
Number of subjects: 947
Study 32835465 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Intensive Management (PIM)
Number of subjects: 1527
Study 35082847 — intervention group
Group type: EXPERIMENTAL
Intervention: NSPT with periodontal endoscopy (PE)
Number of subjects: 20
Study 35082847 — intervention group
Group type: COMPARATOR
Intervention: NSPT without periodontal endoscopy (nPE)
Number of subjects: 20
Study 33566129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v administered for 60 days
Number of subjects: 218
Study 33566129 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 60 days
Number of subjects: 218
Study 33566129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Number of subjects: 218
Study 33566129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 34672100 — intervention group
Group type: EXPERIMENTAL
Intervention: C + T (1 drop of cyclopentolate 1% and 1 drop of tropicamide 1%)
Number of subjects: 251
Study 34672100 — intervention group
Group type: EXPERIMENTAL
Intervention: C + C (2 drops of cyclopentolate 1%)
Number of subjects: 251
Study 32877582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate‐taurursodiol (3 g of sodium phenylbutyrate and 1 g of taurursodiol, administered once a day for 3 weeks and then twice a day)
Number of subjects: 137
Study 32877582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 32877582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate‐taurursodiol
Number of subjects: 137
Study 32877582 — intervention group
Group type: COMPARATOR
Intervention: Sodium phenylbutyrate‐taurursodiol and Placebo
Number of subjects: 137
Study 35190815 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy radiation dose with concurrent chemotherapy (docetaxel 25 mg/m2; cisplatin 25 mg/m2)
Number of subjects: 319
Study 35190815 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy radiation dose with concurrent chemotherapy (docetaxel 25 mg/m2; cisplatin 25 mg/m2)
Number of subjects: 319
Study 33400004 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term glucocorticoid treatment
Number of subjects: 9
Study 33400004 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9
Study 34016484 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill treatment
Number of subjects: 1200
Study 34016484 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1200
Study 34712732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral blood oxygen saturation detection
Number of subjects: 90
Study 34712732 — intervention group
Group type: COMPARATOR
Intervention: No intervention specified for control group (no-POCD)
Number of subjects: 90
Study 32814610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led ATO (ATO-A)
Number of subjects: 538
Study 32814610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led ATO (ATO-B)
Number of subjects: 538
Study 32814610 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC-A)
Number of subjects: 538
Study 32814610 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC ATO-B)
Number of subjects: 538
Study 32814610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led ATO
Number of subjects: 538
Study 35687008 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut intake (15% of daily energy from walnuts)
Number of subjects: 192
Study 35687008 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet, no walnuts)
Number of subjects: 192
Study 35687008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 192
Study 33155675 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-based-ART after 4 weeks of rifampicin-based anti-TB therapy
Number of subjects: 102
Study 33155675 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-based-ART after 8 weeks of rifampicin-based anti-TB therapy
Number of subjects: 102
Study 33155675 — intervention group
Group type: COMPARATOR
Intervention: efavirenz only
Number of subjects: 102
Study 33155675 — intervention group
Group type: EXPERIMENTAL
Intervention: rifampicin only therapy for 4 weeks
Number of subjects: 102
Study 33155675 — intervention group
Group type: EXPERIMENTAL
Intervention: rifampicin only therapy for 8 weeks
Number of subjects: 102
Study 35441931 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus oral antidepressant (AD)
Number of subjects: 0
Study 35441931 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral antidepressant (AD)
Number of subjects: 0
Study 32389819 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical revision of midurethral sling (MUS) due to vaginal mesh extrusion
Number of subjects: 464
Study 35175188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen reduction with riboflavin and ultraviolet light (PRT)
Number of subjects: 40
Study 35175188 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study 36018037 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill (aspirin 100 mg, ramipril 2.5/5/10 mg, atorvastatin 20/40 mg)
Number of subjects: 2499
Study 36018037 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2499
Study 32640846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 85
Study 32640846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 32044752 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Therapy, a remotely delivered, cloud‐based rehabilitation program for speech-language disorders, duration: first 20 weeks of program access.
Number of subjects: 2850
Study 35074766 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief decision aids for 3 ARIs (acute otitis media, acute sore throat, acute bronchitis) and video-delivered training
Number of subjects: 122
Study 35074766 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 122
Study 35074766 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief decision aids and training
Number of subjects: 122
Study 33594755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4744
Study 33594755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4744
Study 35987683 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essence inhalation
Number of subjects: 121
Study 35987683 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essence massage
Number of subjects: 121
Study 35987683 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 121
Study 34362787 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU per day
Number of subjects: 2166
Study 34362787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2166
Study 32465406 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP treatment (16 treatments in the first three months)
Number of subjects: 40
Study 32465406 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard triple immunosuppression: tacrolimus, mycophenolate mofetil, and steroids)
Number of subjects: 40
Study 36369261 — intervention group
Group type: EXPERIMENTAL
Intervention: Female peer mentor
Number of subjects: 150
Study 36369261 — intervention group
Group type: COMPARATOR
Intervention: Male peer mentor
Number of subjects: 150
Study 36369261 — intervention group
Group type: COMPARATOR
Intervention: No mentor
Number of subjects: 150
Study 35842776 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional atherectomy system (DAS)
Number of subjects: 60
Study 35842776 — intervention group
Group type: COMPARATOR
Intervention: Orbital atherectomy system (OAS)
Number of subjects: 60
Study 34939347 — intervention group
Group type: EXPERIMENTAL
Intervention: Jintiange capsule for 3 months
Number of subjects: 106
Study 34939347 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative treatment
Number of subjects: 106
Study 32321301 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients
Number of subjects: 90
Study 32321301 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control)
Number of subjects: 90
Study 32321301 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients with non‐proliferative diabetic retinopathy
Number of subjects: 90
Study 32321301 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients with proliferative diabetic retinopathy
Number of subjects: 90
Study 35761367 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume haemodiafiltration (aiming for 21+ L of substitution fluid adjusted for body surface area)
Number of subjects: 0
Study 35761367 — intervention group
Group type: COMPARATOR
Intervention: High-flux haemodialysis
Number of subjects: 0
Study 33148945 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein oral nutrition supplement containing HMB
Number of subjects: 0
Study 33148945 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Number of subjects: 0
Study 36482636 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU combined with TACE
Number of subjects: 110
Study 36482636 — intervention group
Group type: COMPARATOR
Intervention: TACE (comparison group)
Number of subjects: 110
Study 32396664 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-11
Number of subjects: 196
Study 32396664 — intervention group
Group type: COMPARATOR
Intervention: ICD-10
Number of subjects: 196
Study 32396664 — intervention group
Group type: COMPARATOR
Intervention: DSM-5
Number of subjects: 196
Study 32579567 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert Program® intervention (8-week program, 8 one-hour lessons)
Number of subjects: 271
Study 36166027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen
Number of subjects: 711
Study 36166027 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 711
Study 32651093 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐hour training in sleep leadership
Number of subjects: 524
Study 32651093 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 524
Study 35580297 — intervention group
Group type: EXPERIMENTAL
Intervention: Aumolertinib (110 mg once daily)
Number of subjects: 429
Study 35580297 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg once daily)
Number of subjects: 429
Study 36088298 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning surgery group (group A, 8:00–12:00)
Number of subjects: 59
Study 36088298 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon surgery group (group P, 14:00–18:00)
Number of subjects: 59
Study 36088298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (morning and afternoon surgeries)
Number of subjects: 59
Study 34967165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol + Canephron N (2 tablets t.i.d. for 2 weeks)
Number of subjects: 112
Study 34967165 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin trometamol (3 g, single dose)
Number of subjects: 112
Study 34967165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol + Canephron N
Number of subjects: 112
Study 34114918 — intervention group
Group type: EXPERIMENTAL
Intervention: Longvida® optimized curcumin (1.0 g/day)
Number of subjects: 36
Study 34114918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 36
Study 32966051 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortest-distance routes
Number of subjects: 14091
Study 32966051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative lowest-dose route
Number of subjects: 14091
Study 32966051 — intervention group
Group type: COMPARATOR
Intervention: Simulated addresses
Number of subjects: 14091
Study 32966051 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure inequality analysis
Number of subjects: 14091
Study 35908118 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 long chain polyunsaturated fatty acids (LCPUFA)
Number of subjects: 300
Study 34144486 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for a median of 28 days
Number of subjects: 108
Study 35664504 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground wearable-exoskeleton training
Number of subjects: 50
Study 35664504 — intervention group
Group type: COMPARATOR
Intervention: Functional kinematic therapy
Number of subjects: 50
Study 32029450 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol
Number of subjects: 407
Study 32029450 — intervention group
Group type: COMPARATOR
Intervention: Maintenance budesonide
Number of subjects: 407
Study 36829111 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-µg FAKHRAVAC vaccine
Number of subjects: 500
Study 36829111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 33689709 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 12515
Study 32857128 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB+D + no exercise
Number of subjects: 117
Study 32857128 — intervention group
Group type: COMPARATOR
Intervention: Control + no exercise
Number of subjects: 117
Study 32857128 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB+D + exercise
Number of subjects: 117
Study 32857128 — intervention group
Group type: COMPARATOR
Intervention: Control + exercise
Number of subjects: 117
Study 36116775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of dexamethasone per day for 1 to 2 days
Number of subjects: 0
Study 36116775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of dexamethasone per day for 1 to 2 days
Number of subjects: 0
Study 36116775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 0
Study 36116775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of dexamethasone
Number of subjects: 0
Study 36116775 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of dexamethasone
Number of subjects: 0
Study 32785666 — intervention group
Group type: EXPERIMENTAL
Intervention: VEN + R (arm A)
Number of subjects: 163
Study 32785666 — intervention group
Group type: EXPERIMENTAL
Intervention: VEN + BR (arm B)
Number of subjects: 163
Study 32785666 — intervention group
Group type: COMPARATOR
Intervention: BR (arm C)
Number of subjects: 163
Study 34138817 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (END)
Number of subjects: 78
Study 34138817 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 78
Study 32801090 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS to the left anterior STG (laSTG)
Number of subjects: 20
Study 32801090 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS to the left posterior STG (lpSTG)
Number of subjects: 20
Study 32801090 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS to the right anterior STG (raSTG)
Number of subjects: 20
Study 32801090 — intervention group
Group type: COMPARATOR
Intervention: Control region (posterior occipital lobe)
Number of subjects: 20
Study 35952357 — intervention group
Group type: EXPERIMENTAL
Intervention: ART during breastfeeding cessation
Number of subjects: 55
Study 35952357 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TFV levels
Number of subjects: 55
Study 33740407 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience-based psychosocial HIV prevention intervention (group and individual counselling, HIV and STI voluntary counselling and testing)
Number of subjects: 608
Study 33740407 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control (voluntary counselling and testing alone)
Number of subjects: 608
Study 34983010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 20 IU
Number of subjects: 47
Study 34983010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 40 IU
Number of subjects: 47
Study 34983010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous threat (PTSD-AUD only)
Number of subjects: 47
Study 34161523 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable shoes
Number of subjects: 0
Study 34161523 — intervention group
Group type: COMPARATOR
Intervention: Conventional shoes
Number of subjects: 0
Study 35630046 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cue deprivation balance training with head control feedback
Number of subjects: 41
Study 35630046 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study 33980512 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPER exercise intervention
Number of subjects: 20
Study 33980512 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 20
Study 32584290 — intervention group
Group type: EXPERIMENTAL
Intervention: Face‐to‐face health counseling on SHS
Number of subjects: 100
Study 32584290 — intervention group
Group type: COMPARATOR
Intervention: Written educational pamphlet only (Control)
Number of subjects: 100
Study 36435397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS + agomelatine
Number of subjects: 100
Study 36435397 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS + agomelatine
Number of subjects: 100
Study 34015036 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (2 puffs of 200 μg) 30 min before anesthesia induction and 30 min before surgery completion
Number of subjects: 63
Study 34015036 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 63
Study 33345816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous protocol (intravenous paracetamol 3 times daily with oral ibuprofen twice daily)
Number of subjects: 127
Study 33345816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protocol (oral paracetamol 3 times daily with oral ibuprofen twice daily)
Number of subjects: 127
Study 33345816 — intervention group
Group type: COMPARATOR
Intervention: On-demand protocol (oral paracetamol or ibuprofen or dipyrone based on visual analog scale)
Number of subjects: 127
Study 33345816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous protocol
Number of subjects: 127
Study 33345816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protocol
Number of subjects: 127
Study 33345816 — intervention group
Group type: COMPARATOR
Intervention: On-demand protocol
Number of subjects: 127
Study 35367870 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (F, 20% carbohydrates, 60% fat)
Number of subjects: 12
Study 35367870 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet (C, 35% carbohydrates, 45% fat)
Number of subjects: 12
Study 35367870 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (F) in subjects with rare variant in LPL gene
Number of subjects: 12
Study 35367870 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet (C) in subjects with rare variant in LPL gene
Number of subjects: 12
Study 33245749 — intervention group
Group type: EXPERIMENTAL
Intervention: CDR132L (0.32, 1, 3, and 10 mg/kg body weight)
Number of subjects: 28
Study 33245749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 28
Study 33245749 — intervention group
Group type: EXPERIMENTAL
Intervention: CDR132L (≥1 mg/kg)
Number of subjects: 28
Study 33472201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) until the 36th week of gestation
Number of subjects: 278
Study 33472201 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 278
Study 35525940 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL)
Number of subjects: 0
Study 35525940 — intervention group
Group type: COMPARATOR
Intervention: Interactive lecture (IL)
Number of subjects: 0
Study 36155316 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health intervention for 24 weeks
Number of subjects: 66
Study 36155316 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 66
Study 33373708 — intervention group
Group type: EXPERIMENTAL
Intervention: iTind
Number of subjects: 175
Study 33373708 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 175
Study 32764918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 100μg/vilanterol (VI) 25μg
Number of subjects: 16485
Study 32764918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16485
Study 33742775 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h modified N-acetylcysteine (NAC) regimen
Number of subjects: 45
Study 33742775 — intervention group
Group type: COMPARATOR
Intervention: 20.25 h standard N-acetylcysteine (NAC) regimen
Number of subjects: 45
Study 33742775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 45
Study 33742775 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma APAP and purine metabolites
Number of subjects: 45
Study 33726695 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric case management
Number of subjects: 3200
Study 33726695 — intervention group
Group type: COMPARATOR
Intervention: Standard care (care as usual)
Number of subjects: 3200